Management of Left Ventricular Hypertrophy

Etiology-Based Management Approach

• The American Heart Association recommends that ARBs, particularly losartan, are preferred first-line agents for LVH regression due to superior efficacy in reducing left ventricular mass and myocardial fibrosis compared to beta-blockers 2
• The European Society of Cardiology suggests that ACE inhibitors are equally effective alternatives when ARBs aren't tolerated 2
• The American College of Cardiology recommends that non-vasodilating β-blockers titrated to maximum tolerated dose are first-line therapy for symptomatic patients with LVOTO 3, 4
• The European Heart Journal states that disopyramide may be added to β-blockers, which can abolish basal LV outflow pressure gradients and improve exercise tolerance in patients with LVOTO 3, 4

General Management Principles

• The European Society of Cardiology recommends that echocardiography is more sensitive than electrocardiography in detecting LVH and should be used for diagnosis and monitoring 6
• The American Heart Association suggests that proper evaluation includes measurements of interventricular septum, LV posterior wall thickness, end-diastolic diameter, and calculation of LV mass 6
• The European Heart Journal states that diastolic dysfunction is common in LVH and contributes to decreased exercise capacity and adverse prognosis 1, 8
• The American College of Cardiology recommends that prompt restoration of sinus rhythm or appropriate rate control should be considered in patients with new-onset or poorly controlled atrial fibrillation 3

Clinical Benefits of LVH Regression

• The American Heart Association suggests that treatment-induced reduction in left ventricular mass is significantly and independently associated with reduction in major cardiovascular events, stroke, and cardiovascular and all-cause mortality 1, 8

Common Pitfalls and Caveats

• The European Heart Journal warns that nifedipine and other dihydropyridine calcium antagonists are not recommended for treatment of LVOTO 5
• The American College of Cardiology recommends that low-dose loop or thiazide diuretics may be used cautiously to improve dyspnea associated with LVOTO, but it's essential to avoid hypovolaemia 5
• The European Society of Cardiology states that using dobutamine to identify latent LVOTO is not advised due to lack of specificity 1, 8